ArticleFrontiers in immunology2026
A multicenter retrospective cohort study on the efficacy and safety of mycophenolate mofetil plus hydroxychloroquine therapy in IgA nephropathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mechanisms of action of mycophenolate mofetil (MMF) and hydroxychloroquine (HCQ) differ in the treatment of IgA nephropathy (IgAN), and the two may have a synergistic effect in delaying disease progression. Methods: This multicenter retrospective cohort study included patients aged 18-60 years with biopsy-confirmed primary IgAN, with 83 patients receiving MMF plus HCQ (combined group) and 94 receiving MMF alone (MMF group). All patients had an estimated glomerular filtration rate > 45 ml/min/1.73 m Results: After matching, the CR rates at 12 months were 63.8% (37/58) and 37.9% (22/58) in the combination and MMF groups, respectively (odds ratio: 0.59, 95% CI 0.40-0.87, Conclusion: Combination therapy with MMF and HCQ was associated with higher remission rates and greater reduction in UP at 12 months, particularly among those with baseline UP >2 g/d or eGFR between 45 and 60 mL/min/1.73 m², supporting its potential short-term renal benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.